109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
Sub-classes:MICRORNA-134 BIOMARKER
#2INHIBITION OF SMOOTH MUSCLE CELL CONTRACTION BY ALTERING INTERLEUKIN 31 RECEPTOR ALPHA LEVELS
#3METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES AND DISORDERS AND CANCERS
#4MICROEXON TARGETING FOR MODULATION OF RYR2 CHANNEL ACTIVITY
#5COMPOSITIONS AND METHODS FOR TREATMENT OF CANCERS
#6METHODS OF TREATING IMPAIRED GLUCOCORTICOID SIGNALLING IN UTERINE DISORDERS
#7PHARMACEUTICAL COMPOSITION FOR TREATING SPINOCEREBELLAR ATAXIA
#8ANTI-CANCER TGFB2 AGENTS WITH IMMUNOTHERAPEUTICS
#9OLIGONUCLEOTIDE-MEDIATED KNOCKDOWN OF PLN
#10COMPOSITIONS, METHODS, AND KITS RELATING TO THERAPEUTICS FOR THE MODULATION OF SEL1L-HRD1 ERAD ACTIVITY AND FUNCTION
#11OLIGONUCLEOTIDES
#12RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF
#13ENGINEERED CONSTRUCTS FOR INCREASED TRANSCRIPTION OF RNA PAYLOADS
#14METHODS FOR TREATING MUSCULAR DYSTROPHY
#15Compositions for Modulating C9ORF72 Expression
#16COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAME
#17SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR IDIOPATHIC PULMONARY FIBROSIS
#18COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION
#19COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#20ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP
#21COMPOSITIONS AND METHODS COMPRISING PROGRAMMABLE SNRNAS FOR RNA EDITING
#22NOVEL MICROBIAL GENOTOXINS
#23Synergistic Nucleic Acid Based Therapeutics and Methods of Use for Treating Genetic Disorders
#24ANTI-CANCER TGFB2 AGENTS WITH IMMUNOTHERAPEUTICS
#25CANCER-TARGETED, VIRUS-ENCODED, REGULATABLE T (CATVERT) OR NK CELL (CATVERN) LINKERS
#26Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations
#27ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
#28STABILIZED RNA AGENTS
#29METHODS OF TREATING CANCERS
#30Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
#31NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#32TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE
#33DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF
#34RNA MOLECULES
#35DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY
#36USE OF MIR-15A-5P IN TREATMENT OF FUNDUS OCULI DISEASE
#37RUNX1 MODULATORS
#38POMPE DISEASE MOUSE MODEL GENERATION, CHARACTERIZATION AND METHODS OF USE
#39ANTISENSE OLIGONUCLEOTIDE, COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS THEREOF FOR EXON SKIPPING
#40COMPOSITIONS AND METHODS FOR TREATING MYOPATHY
#41COMPOSITIONS AND METHODS FOR TREATING PRIMARY CILIARY DYSKINESIA
#42LONG NON-CODING RNAS AS TARGET FOR TREATING FIBROSIS AND CANCER
#43DRUG DELIVERY SYSTEM FOR BLOOD-BRAIN BARRIER PENETRATION
#44Compounds and Methods for Reducing ATXN3 Expression
#45METHODS FOR GENE TRAINING
#46COMPOSITIONS AND METHODS TO MODULATE TUMOR MICROENVIRONMENT ASSOCIATED LONG NONCODING RNAS
#47THERAPEUTIC OLIGONUCLEOTIDES TO CORRECT CYSTIC FIBROSIS MUTATIONS
#48METHODS, SYSTEMS, AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHY (E.G., BETA-THALASSEMIA AND SICKLE CELL DISEASE) BY INCREASING EXPRESSION OF NONCODING RNA ACTIVATED BY DNA DAMAGE
#49CELLULAR COMPOSITIONS AND METHODS OF TREATMENT I
#50POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#51NOVEL COMPOUND AND APPLICATION THEREOF
#52NOVEL COMPOUND AND APPLICATION THEREOF
#53Antisense oligonucleotides for treatment of USHER 2A. Exon 68
#54KLRG1 SIGNALLING THERAPY FOR INFECTIOUS DISEASE
#55COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION
#56RNA AND DNA BASE EDITING VIA ENGINEERED ADAR RECRUITMENT
#57NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#58CELL-PENETRATING PEPTIDES
#59TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
#60MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROME
#61THERAPEUTIC AGENTS FOR METABOLISM-ASSOCIATED DISEASES
#62GALNAC MONOMER COMPRISING RIBOSE RING OR DERIVATIVE STRUCTURE THEREOF AND USE THEREOF IN LIVER-TARGETED DELIVERY OF SMALL NUCLEIC ACID DRUGS
#63COMPOSITIONS FOR USE IN THE TREATMENT OF CHD2 HAPLOINSUFFICIENCY
#64Methods for Treating Cancer Using a Stat3 Double-Stranded, Cyclic Oligonucleotide Decoy
#65SIRNA FOR TARGETED INHIBITION OF AGT GENE EXPRESSION AND USE THEREOF IN TREATING HYPERTENSION
#66COMPOUNDS AND METHODS FOR MODULATING SMN2
#67ANTISENSE OLIGONUCLEOTIDE TARGETING TDP-43 MRNA OR PRE-MRNA
#68RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS
#69METHODS TO TREAT NEURODEGENERATIVE DISORDERS BY REDUCING NUCLEAR AGGREGATES AND MODULATING ADENOSINE-TO-INOSINE RNA EDITING
#70Cyclic Antisense Therapeutics
#71SELF-CIRCULARIZATION RNA STRUCTURE
#72METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER
#73METHODS FOR TREATING CANCER WITH HYPERACTIVE ADAR ENZYMES
#74DSRNA, USE THEREOF AND PREPARATION METHOD THEREFOR
#75SPLICE-SWITCHING OLIGONUCLEOTIDES TARGETING IL-4RA
#76Fibroblast Growth Factor (FGF)21 Inhibition for Treatment of Cardiac Hypertrophy
#77Oral Delivery of Antisense Conjugates Targeting PCSK9
#78OLIGONUCLEOTIDES FOR MODULATING REGULATORY T CELL MEDIATED IMMUNOSUPPRESSION
#79SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF
#80Treatment Of Pan-Cancer Phenotype With Regulator of Telomere Elongation Helicase 1 (RTEL1) Inhibitors
#81Delivery of RNA Therapeutics Using Circular Prodrug Nucleic Acids
#82COMPOSITIONS AND METHODS FOR TREATING MENINGIOMA
#83METHODS AND COMPOSITIONS FOR MODULATING SPLICING AT ALTERNATIVE SPLICE SITES
#84CLONING AND EXPRESSION SYSTEM FOR T-CELL RECEPTORS
#85NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#86LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOF
#87MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS
#88TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#89Therapeutic Strategies To Reduce Thrombotic Risk In Factor V Leiden (FVL) Carriers
#90GalNAc Compound Containing Triazole Structure and Oligonucleotide Conjugate Thereof
#91ANTISENSE OLIGONUCLEOTIDE FOR INHIBITING ACSL4 GENE EXPRESSION AND ITS APPLICATIONS
#92ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS
#93METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A)
#94REGULATION OF ACTIVITY OF RNAI MOLECULES
#95COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
#96METHODS FOR DECREASING OR INHIBITING HUMAN L1 RETROTRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN
#97TREATMENT OF SPINAL MUSCULAR ATROPHY
#98LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER
#99RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
#100METHODS AND COMPOSITIONS FOR GENERATING DOMINANT ALLELES USING GENOME EDITING
#101Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#102METHODS AND COMPOSITIONS FOR TARGETING SERINE DEHYDRATASE
#103OLIGONUCLEOTIDES FOR PRNP MODULATION
#104COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#105ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES
#106AGGREGATION-RESISTANT VARIANTS OF TDP-43
#107SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER
#108NUCLEIC ACID AGENTS MODULATING FAS ISOFORMS
#109HYBRID OLIGONUCLEOTIDES
#110AGENTS FOR MODULATING EXPRESSION
#111RNAi AGENTS OF PRION EXPRESSION
#112EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA
#113ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF
#114Compositions and Methods for Modulating Complement Factor B Expression
#115Use Of Serine/Arginine-Rich Splicing Factor 1 (SRSF1) As Therapeutic Target For Aortic Dissection
#116PHASE TRANSITION ADJUSTING ELEMENT AND USE THEREOF
#117RNAI AGENTS FOR INHIBITING EXPRESSION OF HUNTINGTIN (HTT), COMPOSITIONS THEREOF, AND METHODS OF USE
#118LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION
#119Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
#120DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE
#121COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY TARGETING THE BRCA1 PSEUDOGENE (BRCA1P1)
#122TXNIP INHIBITION TO ENHANCE ADOPTIVE IMMUNOTHERAPY
#123POLYMER NANOPARTICLE AND DNA NANOSTRUCTURE COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERY
#124RNAi Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of Use
#125ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#126ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
#127MODIFYING THE SPECIFICITY OF PLANT NON-CODING RNA MOLECULES FOR SILENCING GENE EXPRESSION
#128COMPOUND FOR INHIBITING AGT GENE EXPRESSION, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
#129COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER
#130OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#131SIRNA TARGETING AND REGULATING PCSK9 GENE EXPRESSION AND USE THEREOF
#132VESICLE-BASED COMPOSITIONS AND USES THEREOF
#133MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF
#134COMPOSITIONS AND METHOD FOR THE TREATMENT OF X-LINKED DYSTONIA PARKINSONISM
#135ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW
#136IONIZABLE LIPID CONTAINING BIODEGRADABLE DISULFIDE BOND AND LIPID NANOPARTICLES COMPRISING SAME
#137OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#138Methods and Compositions for Adar-Mediated Editing
#139Compositions and Methods for Inhibition of Factor XII Gene Expression
#140RNA INTERFERENCE OLIGONUCLEOTIDES FOR INHIBITING PERINEURONAL NETWORK FORMATION
#141SMALL ACTIVATING RNA (saRNA) CAPABLE OF ACTIVATING CCAAT ENHANCER BINDING PROTEIN ALPHA (CEBPA) GENE, AND DELIVERY SYSTEM AND USE THEREOF
#142CELL-PENETRATING PEPTIDES
#143IONIZABLE LIPIDS FOR MULTIPLE ORGAN TARGETING
#144METHODS FOR MANUFACTURING AND USING EXTRACELLULAR VESICLES
#145GENERATION OF NEURONS BY REPROGRAMMING OF OLIGODENDROCYTES AND OLIGODENDROCYTE PRECURSOR CELLS
#146SIRNA TARGETING RECQL1 HELICASE GENE
#147CANCER THERAPY WITH TGF-BETA-2 AND IRINOTECAN AGENTS
#148METHODS AND COMPOSITIONS FOR INHIBITING VIRUS
#149SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF
#150NOVEL RNA THERAPEUTICS AND USES THEREOF
#151METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6
#152COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH PATHOGENIC FUS VARIANTS
#153MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#154NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#155RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of Use
#156THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF
#157Selective Antisense Compounds and Uses Thereof
#158SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT CANCER
#159MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS
#160Linkage Modified Oligomeric Compounds and Uses Thereof
#161Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#162OLIGONUCLEOTIDES
#163TREATMENT OF MS4A4E RELATED DISEASES AND DISORDERS
#164Compositions and Methods for Treating FUS Associated Diseases
#165MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY
#166CHIMERIC PEPTIDES FOR ANTISENSE DELIVERY
#167NANOPARTICLE COMPOSITIONS CONTAINING SIRP-alpha siRNA FOR TREATMENT OF CANCER
#168ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
#169MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#170MRNA COMPOSITION FOR REGULATING MRNA TRANSLATION COMPRISING MRNA AND ANTISENSE OLIGONUCLEOTIDE COMPLEMENTARY TO PORTION OF THE MRNA
#171NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES
#172METHODS OF TREATING X-LINKED GENETIC DISEASES
#173L-RNA APTAMER-ANTISENSE OLIGONUCLEOTIDE CONJUGATES AND USES THEREOF
#174DUAL-ACTING siRNA BASED MODULATION OF C9orf72
#175Antisense Compounds Targeted to CLN3 and Uses Thereof
#176TARGETING MUC1-C WITH A NOVEL ANTISENSE OLIGONUCLEOTIDE FOR THE TREATMENT OF CANCER
#177COMPOSITION FOR TREATING CANCER
#178FUNCTIONAL NUCLEIC ACID MOLECULE
#179TARGETING ARHGAP5 GENE FUNCTION IN CANCER WITH ARHGAP35 ALTERATION
#180CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#181Antisense Oligonucleotide for Targeting Progranulin
#182WIDE RANGE SYNTHETIC PEPTIDE NUCLEIC ACIDS AND THEIR APPLICATIONS
#183COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY
#184COMPOSITIONS AND METHODS FOR MODULATING CONDITIONS ASSOCIATED WITH ALTERED ATP8B1 FUNCTION
#185Method For Treating Cyclophilin B Associated Diseases
#186ANTISENSE OLIGONUCLEOTIDES
#187COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#188RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use
#189RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF
#190COMPOUNDS AND METHODS FOR REDUCING PCDH19 EXPRESSION
#191MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
#192METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#193TREATING TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED DISEASES
#194Polynucleotide Treatments for Charcot-Marie-Tooth Disease
#195COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
#196Conjugated Antisense Compounds and Their Use
#19717ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#198BBB-CROSSING LIPID LIGAND OF HETERO NUCLEIC ACID
#199Antisense oligonucleotides for the treatment of Stargardt disease
#200TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS
#201SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF
#202Targeting Skin-Related Conditions Using Bottlebrush Polymer-Conjugated Oligonucleotides
#203ANTISENSE MODULATION OF SETBP1 EXPRESSION
#204CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS FOR RNA EDITING
#205OLIGONUCLEOTIDES FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#206ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
#207SUSTAINED RELEASE NUCLEIC ACID FORMULATIONS FOR TREATMENT OF PERIPHERAL NERVE DEMYELINATION
#208USE OF MYOSTATIN INHIBITOR FOR TREATING SPINAL MUSCULAR ATROPHY
#209Compounds and Methods for Reducing KCNT1 Expression
#210PALMITOYLATION OF THE ALTERNATIVE AMINO TERMINUS OF THE BTK-C ISOFORM CONTROLS SUBCELLULAR DISTRIBUTION AND SIGNALING
#211COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION
#212METHODS FOR REDUCING TAU EXPRESSION
#213NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
#214METHODS FOR TREATING HYPERCHOLESTEROLEMIA
#215Compounds and Methods for Reducing LRRK2 Expression
#216TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#217MUCIN-5B (MUC5B) TARGETED SIRNA AND ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#218NUCLEIC ACID FOR TRANSFECTION
#219MICELLAR NANOPARTICLES AND USES THEREOF
#220RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF
#221ANTISENSE OLIGONUCLEOTIDE FOR TREATING MELANOMA
#222COMPOSITIONS FOR TREATING SYNGAP-1 RELATED NEURODEVELOPMENTAL DISORDERS
#223Methods for Reducing Ataxin-2 Expression
#224UBE3A ANTISENSE THERAPEUTICS
#225COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A
#226STEREOSPECIFIC LINKAGES IN RNA EDITING OLIGONUCLEOTIDES
#227METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION THROUGH BLOCKING OF HNRNP R-MEDIATED MAPT MRNA TRANSPORT FOR TREATMENT OF ALZHEIMER'S DISEASE
#228METHODS AND COMPOSITIONS OF VIRUS-LIKE PARTICLES OF CYTOPLASMIC TYPE CITRUS LEPROSIS VIRUS FOR NANOTECHNOLOGY APPLICATIONS
#229HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
#230Saponin Conjugates
#231RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use
#232IMMUNE CELL WITH DOWN-REGULATED CELL ADHESION CAPABILITY AND MEDICAL USE THEREOF
#233REGULATION OF TYPE I IFN SIGNALING BY TARGETING A DECOY RECEPTOR
#234OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF
#235SPLICE-SWITCHING OLIGONUCLEOTIDES
#236COMPOUNDS AND METHODS FOR MODULATING ATXN1
#237ARTIFICIAL RNA MOLECULE
#238Nucleic acid regulation of SNCA
#239ANTISENSE OLIGONUCLEOTIDE COMPLEX
#240METHODS AND COMPOSITIONS FOR INHIBITING MISMATCH REPAIR
#241MUC5AC-TARGETED ANTISENSE OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING MUCIN EXPRESSION
#242MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#243ISOLATION OF ANTI-INFLAMMATORY NEUTROPHIL OR MONOCYTE SUBSET AND USE IN TREATING CARDIOVASCULAR DISEASES
#244DIFFERENTIAL ALTERNATIVE SPLICING IN RELAPSED AND REFRACTORY DIFFUSE LARGE-B CELL LYMPHOMA PATIENTS RECEIVING CAR-T THERAPY
#245USE OF ANTISENSE OLIGONUCLEOTIDE IN PREPARATION OF DRUG FOR TREATING DISEASE CAUSED BY ABNORMAL THYROID
#246TARGETED TREATMENT OF SPLICEOPATHY-INDUCED NEUROLOGICAL DISORDERS
#247CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING
#248MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#249STAT3 TARGETING OLIGONUCLEOTIDES AND USES THEREOF
#250EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
#251IMPROVED OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
#252LOCALIZATION OF TRANS-SPLICING NUCLEIC ACID MOLECULES TO AND WITHIN THE CELLULAR NUCLEUS
#253METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA
#254MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
#255COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY DISEASE
#256Oligonucleotide Terminal Phosphate Derivatives and Method of Use
#257MAPT ANTISENSE OLIGONUCLEOTIDE
#258COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A
#259GENE THERAPY OF HIPPO SIGNALING IMPROVES HEART FUNCTION IN A CLINICALLY RELEVANT MODEL
#260TREATMENT OF CARDIOVASCULAR DISEASE
#261COMPOSITIONS FOR TARGETING FLI-1 AND METHODS OF USE THEREOF
#262CLUSTERIN OVEREXPRESSION IN ALZHEIMER’S DISEASE
#263MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDES
#264FN3 DOMAIN-siRNA CONJUGATES AND USES THEREOF
#265Allele-Specific Silencing of Transforming Growth Factor Beta Induced Gene with R124H Mutation Using Short Interfering RNA
#266SPLICE SWITCHING OLIGONUCLEOTIDES TARGETING PSEUDOEXONS
#267COMPOSITIONS AND METHODS RELATED TO MULTIPLE MYELOMA-ASSOCIATED LONG NONCODING RNAS
#268BIODIFFUSION CHAMBER
#269MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#270TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
#271FUNCTIONAL NUCLEIC ACID MOLECULES
#272ANTI-CANCER AGENTS
#273COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION
#274COMPOUNDS AND METHODS FOR MODULATING SCN2A
#275Selective Antisense Compounds and Uses Thereof
#276STABILIZATION OF THERAPEUTIC TRANS-SPLICING RNA MOLECULES IN HUMAN CELLS
#277Cyclic Structured Oligonucleotides as Therapeutic Agents
#278COMPOSITIONS AND METHODS FOR TREATING TARDBP ASSOCIATED DISEASES
#279NUCLEIC ACID DELIVERY SYSTEM
#280PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV
#281METHOD OF TREATING, AMELIORATING AND/OR PREVENTING POLYCYSTIC KIDNEY DISEASE
#282COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH siRNAS TARGETING TBX3
#283PHARMACEUTICAL USE OF FAM19A5 INVOLVED IN REGULATING GLIOGENESIS
#284COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A))
#285Antisense oligonucleotides for treatment of USHER 2A. Exons 30-31
#286METHOD OF REGULATING ALTERNATIVE POLYADENYLATION IN RNA
#287P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION
#288MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS
#289SIRNA OR SALT THEREOF AND MEDICAMENT FOR INHIBITING EXPRESSION OF TMPRSS6 GENE, AND USE THEREOF
#290POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
#291DOUBLE-STRANDED RNA MOLECULE FOR ADMINISTRATION TO THE EYE
#292TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION – UPREGULATION 1 (ACT-UP1) AND USES THEREOF
#293PEPTIDE-BASED DELIVERY AGENT WITH ASPARAGINE-CONTAINING MASK PEPTIDE GROUP AND METHOD OF MAKING AND USING THE SAME
#294PROTOZOA TRANSCRIPTION FACTOR INHIBITOR
#295OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES
#296COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS
#297MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#298SARM1 RNAi AGENTS
#299DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING MYOTONIC DYSTROPHY
#300LIPID NANOPARTICLES, NUCLEIC ACIDS, AND METHODS OF USE